Article

Shire Acquires Baxalta in $32 Billion Deal

Shire’s acquisition of Baxalta creates a leading company for rare disease drugs.

Shire and Baxalta have announced $32 billion agreement under which Shire will combine with Baxalta, creating a company with the top rare diseases platform in revenue and pipeline depth, the companies reported in a Jan. 11, 2016 press statement. The new company is projected to achieve annual revenues of $20 billion by 2020.

Shire reports that the combined companies will have products in growing franchises in hematology; immunology; neuroscience; lysosomal storage diseases; gastrointestinal/endocrine; hereditary angioedema; and oncology; as well as a late-stage ophthalmics pipeline.

Baxalta shareholders will hold approximately 34% ownership in the combined company. The parties expect the transaction to close mid-2016.

Source: Shire

 

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related Videos
Tariffs & Trade Policy: Results of a Bio/Pharma Peer Survey
How the 15% US-EU Tariff Cap Affects Bio/pharma
Dave Miller, PhD, Chief Scientific Officer, AustinPx
© 2025 MJH Life Sciences

All rights reserved.